Last mentioned: Mar 16, 2026
Refusal to File
FDA's Vinay Prasad issues a formal refusal to review the flu vaccine application.
Grant Rescissions
The White House rescinds hundreds of millions in mRNA research funding.
Workaround Support
FDA officials reportedly signal acceptance of Moderna's alternative trial data submission.
Flu Vaccine Collaboration
Moderna begins working with the FDA on trial designs for its mRNA flu vaccine.
Peak Valuation
Moderna reaches a $200 billion market cap following global vaccine success.
The FDA's rare 'refusal to file' regarding Moderna's mRNA flu vaccine signals a pivot from pandemic-era collaboration to a more adversarial regulatory environment. This unpredictability, combined with rescinded federal grants and a 90% decline in market value, highlights the growing legal and compliance risks for biotech firms.
This page surfaces every story mentioning Vinay Prasad across our legal coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running legal beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Vinay Prasad was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |